You are here

Home › Pfizer/BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose Vaccine Candidate Against COVID-19 and Influenza › Pfizer/BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose Vaccine Candidate Against COVID-19 and Influenza

Pfizer/BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose Vaccine Candidate Against COVID-19 and Influenza

Primary tabs

Pfizer/BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose Vaccine Candidate Against COVID-19 and Influenza

Mon, 2022-12-12 12:59 — mike kraft
Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza | BioNTech NEW YORK and MAINZ, GERMANY, DECEMBER 9, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the companies have received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for their mRNA-based combination vaccine candidate for influenza and COVID-19, BioNTech

...

A combined vaccine for influenza and COVID-19 has the potential to simplify immunization practices against two severe respiratory diseases caused by evolving viruses that require vaccine adaptation.

Country / Region Tags: 
Germany
Global
United States
General Topic Tags: 
COVID-19
Seasonal Flu
Treatments
Contagion
Disease
Disease Prevention
Government
Health
Mutations
Pandemics
Public Health
Research
Vaccinations
Problem, Solution, SitRep, or ?: 
Situation Report
Groups this Group Post belongs to: 
- Private group -
Workflow history
Revision ID Field name Date Old state New state name By Commentaire Operations
No state No state
howdy folks
Page loaded in 0.403 seconds.